Multidrug-Resistant Bacteria in Surgical Intensive Care Units: Antibiotic Susceptibility and β-Lactamase Characterization

Daniela Bandić Pavlović,Mladen Pospišil,Marina Nađ,Vilena Vrbanović Mijatović,Josefa Luxner,Gernot Zarfel,Andrea Grisold,Dinko Tonković,Mirela Dobrić,Branka Bedenić
DOI: https://doi.org/10.3390/pathogens13050411
IF: 3.7
2024-05-16
Pathogens
Abstract:Multidrug-resistant (MDR) bacteria of the utmost importance are extended-spectrum β-lactamase (ESBL) and carbapenemase-producing Enterobacterales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus spp. (VRE). In this study, an evaluation of MDR bacteria in surgical intensive care units in a tertiary referral hospital was conducted. The study aimed to characterize β-lactamases and other resistance traits of Gram-negative bacteria isolated in surgical intensive care units (ICUs). Disk diffusion and the broth dilution method were used for antibiotic susceptibility testing, whereas ESBL screening was performed through a double disk synergy test and an inhibitor-based test with clavulanic acid. A total of 119 MDR bacterial isolates were analysed. ESBL production was observed in half of the Proteus mirabilis, 90% of the Klebsiella pneumoniae and all of the Enterobacter cloacae, P. mirabilis and Escherichia coli isolates. OXA-48 carbapenemase, carried by the L plasmid, was detected in 34 K. pneumoniae and one E. coli and Enterobacter cloacae complex isolates, whereas NDM occurred sporadically and was identified in three K. pneumoniae isolates. OXA-48 positive isolates coharboured ESBLs belonging to the CTX-M family in all but one isolate. OXA-23 carbapenemase was confirmed in all A. baumannii isolates. The findings of this study provide valuable insight of resistance determinants of Enterobacterales and A. baumannii which will enhance surveillance and intervention strategies that are necessary to curb the ever-growing carbapenem resistance rates.
microbiology
What problem does this paper attempt to address?
The paper aims to address the issue of multidrug-resistant bacteria in the surgical intensive care unit (ICU) and to characterize the β-lactamases and other resistance features of these bacteria. Specifically, the study focuses on the following points: 1. **Multidrug-Resistant Bacteria (MDR)**: - The study evaluated multidrug-resistant bacteria in the surgical ICU of a tertiary referral hospital, including Enterobacteriaceae producing extended-spectrum β-lactamases (ESBL) and carbapenemases (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant enterococci (VRE). 2. **Characterization of β-Lactamases**: - The study characterized β-lactamases and other resistance features of Gram-negative bacteria isolated from the surgical ICU. Antibiotic susceptibility was tested using the disk diffusion method and broth microdilution method, and ESBL was screened using the double-disk synergy test and inhibitor-based tests. 3. **Distribution of Resistance Genes**: - Analysis of 119 multidrug-resistant strains revealed that the detection rates of ESBL in Proteus mirabilis, Klebsiella pneumoniae, and Escherichia coli were 50%, 90%, and 100%, respectively. Additionally, OXA-48 carbapenemase was detected in 34 strains of Klebsiella pneumoniae and one strain each of Escherichia coli and Enterobacter complex, while NDM was found only in three strains of Klebsiella pneumoniae. 4. **Resistance Mechanisms**: - The study also explored resistance mechanisms such as the production of β-lactamases, alterations in porin function, and overexpression of efflux pumps. For example, all Acinetobacter baumannii isolates were found to produce OXA-23 carbapenemase. In summary, this study provides important information on resistant bacteria in the surgical ICU, which helps in formulating monitoring strategies and interventions to address the growing issue of carbapenem resistance.